Sinatra suggests that 3 months should be enough time to see a benefit (3) . We administered coenzyme Q 10 for 6 months.
We are most concerned that Dr. Sinatra may be implying that high doses of coenzyme Q 10 might be preferable to ␤-blockade in patients with heart failure. ␤-Blockers substantially improve both mortality and morbidity in patients with heart failure (4). This treatment has been well studied, and the data are conclusive. In contrast, supporters of the use of coenzyme Q 10 can point only to small uncontrolled studies and theoretical concerns. We have no objection to further controlled studies of coenzyme Q 10 . Meanwhile, using anecdotal experience to advocate the use of expensive high doses of a drug shown to be ineffective in controlled studies is inappropriate.
Outcomes of Lyme Disease

TO THE EDITOR:
The recent report by Shadick and colleagues (1) addresses an understudied area of research. Nevertheless, the conclusions reached are surprisingly dismissive. All 14 self-reported symptom items presented in the authors' Table 3 were significantly more prevalent in the patients with Lyme disease than in the controls. Furthermore, the comparisons of the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) subscales presented in Table  4 show that case-patients had significantly worse health-related quality-of-life status than controls. On the basis of the presented data, it appears that the case-patients exhibited significant musculoskeletal sequelae in addition to marked reductions in health-related quality of life. In fact, the conclusion that case-patients "exhibited no sequelae on physical examination" seems to be directly contradicted by the reported finding that knee pain (on physical examination) was significantly more prevalent among case-patients than controls (Table  5) . Moreover, the failure to detect significant differences on the administered psychometric tests may be related to the lack of sensitivity of these instruments to measure potentially subtle neurocognitive sequelae (indeed, none of the 353 study participants was found to be abnormal).
The major problem appears to be an overreliance on the seemingly inappropriate stepwise logistic regression analyses that drive the study conclusions. These models simultaneously examine highly collinear independent variables (such as the SF-36 subscales), although it is well known that the influences of individual collinear variables should not be interpreted without "centering" adjustments or other corrective statistical procedures (2) .
Finally, it is not surprising that the oral antibiotics recommended for early-stage disease (that is, doxycycline and amoxicillin) in the late 1980s were associated with complete recovery, because early Lyme disease is far more responsive to antibiotic therapy than late-stage disease is (3, 4) . The analyses examining characteristics of received antibiotic therapy as risk factors for incomplete recovery should be adjusted for the severity of the presenting symptoms at diagnosis to control for confounding by indication.
Dimitri Prybylski, PhD, MPH
University of Maryland School of Medicine Baltimore, MD 21201 IN RESPONSE: We appreciate Dr. Prybylski's insights. He interprets the findings as we do but arrives at them by way of a different path. We agree that it is striking that 14 self-reported symptoms were more prevalent in patients with previous Lyme disease than in those without. Among the 26 symptoms about which patients were queried, we chose these 14 symptoms to highlight in tabular form because they were more prevalent. We similarly noted the striking deficits in health-related quality of life, as measured by the SF-36, among patients with Lyme disease and believe this to be one of the study's main findings. It is true that the prevalence of knee pain was higher when the joint was taken through its range of motion. In an extensive neurologic and musculoskeletal examination and neurocognitive test battery, the groups overall had strikingly similar findings.
We believe that the lack of significant differences between groups on the psychometric tests is a true finding rather than a result of the lack of sensitivity of the measures. In previous studies, these tests have been sensitive to changes in Lyme encephalopathy. The California Verbal Learning Test and the Trailmaking Tests, in particular, can detect the subtle deficits in attention and learning that occur when Lyme disease affects the brain (1) . To maximize the chance of detecting differences between groups, we selected population controls and adjusted our analysis for age and sex. In so doing, small differences between groups would be more evident, especially when the groups have "higher than normal" cognitive performance.
The univariate analyses of the risk factors for incomplete recovery were exploratory but important enough to include in the manuscript. Small numbers called for conservative inference. Much work must be done to understand the relative contribution of treatment delay, type of antibiotic therapy, and initial Lyme disease symptoms in relation to long-term recovery. This would be work for future study.
With regard to the use of stepwise logistic regression, we severely limited the stock of predictors in stepwise models and did not have collinearity. We applied a Bonferroni correction, however, because we tested many possible relationships. By doing so, we created the impression for readers that the differences were small and possibly spurious, but we retained the idea that case-patients had many more conditions. Selvin's viewpoint about stepwise procedures is useful but by no means universal (2 In Rudolph and colleagues' study (1), the cancer incidence in patients with Barrett esophagus segments longer than 10 cm was substantially higher than the incidence in patients whose segment was less than 3 cm long (7 per 100 person-years vs. 2.5 per 100 person-years). The authors concluded that the risk for esophageal adenocarcinoma in patients with short-segment Barrett esophagus was not substantially lower than that in patients with longer segments. However, the study did not have enough power to adequately detect statistically significant differences in the risk for cancer between these two groups of patients while controlling for potential confounders.
Potential confounders of the association between Barrett segment length and cancer risk included baseline dysplasia, age, sex, ethnicity, duration of heartburn, cigarette use, and body mass index. Cox proportional hazards multivariable analysis was used to isolate and quantify the risk associated with the length of Barrett segment while controlling for confounders. As stated in the Methods section, nine potential confounders were examined in a model that contained a maximum predicting 40 outcome events (that is, all patients with cancer). Furthermore, when the analysis was restricted to patients with no baseline dysplasia, it pertained to only eight patients with cancer. On the basis of a commonly used heuristic requiring 10 to 15 outcome events (cancers) for each predictor variable, at least 100 cancers would be needed for the model to be accurate, for the tests of statistical significance to be valid, and for overfitting of the model to be avoided (2, 3) . If, on the other hand, only one or two risk factors were controlled for to accommodate an underpowered model, important potential confounders could be missed and the model would be "underfitted" (2) . Therefore, the proposed negative association between Barrett segment length and risk for cancer must be interpreted with caution.
IN RESPONSE: Assessment of confounding in these analyses was relatively straightforward because none of the risk factors that we examined, with the exception of histologic diagnosis at baseline, was associated to an important degree with both risk for neoplastic progression and segment length at baseline. After it was clear that histologic diagnosis at baseline was a confounder, we evaluated the effects of other potential risk factors by inserting them one or two at a time into a model that also included segment length and histologic diagnosis at baseline. None of these factors was observed to change the relative risk estimate for segment length to an important degree; thus, they were not included in the final models. We did not evaluate all the potential confounders in a single model and do not make any statements to that effect. Multivariate analyses with larger numbers of independent variables would not have been very meaningful given the relatively small number of events in some analyses.
Although our study is the largest yet to examine the relation between segment length and risk for neoplastic progression in patients with Barrett esophagus, we agree that additional follow-up of our cohort and other similar cohorts is needed to measure more precisely any excess risk associated with long segments. Indeed, we made several comments to this effect in the Discussion section. We believe that our conclusion, that the risk for esophageal adenocarcinoma in patients with short-segment Barrett esophagus is not substantially lower than that in patients with longer segments, is appropriately conservative. Calcific Constrictive Pericarditis TO THE EDITOR: Ling and colleagues' article on calcific constrictive pericarditis (1) provided some interesting insights into the clinical spectrum of calcific pericarditis. I am concerned, however, that the article may reflect an unfortunate trend in contemporary medicine and medical education. Nowhere did the article mention the physical examination of constrictive pericarditis or whether examination was used to determine further diagnostic studies. The authors did not discuss the classic findings of a pericardial knock, the Kussmaul sign, and the steep Y decent on the jugular pulse. I trust that a physical examination was done for these patients, but it is important to recognize that the stethoscope still has a place in the diagnosis of most if not all cardiac conditions.
Dennis L. Desilvey, MD
University of Virginia Health System Charlottesville, VA 22908 
Physicians and Patient Spirituality
TO THE EDITOR: Post and colleagues' assertion (1) that "the health care market presses providers in a more holistic direction . . . that includes attentiveness to patient spirituality," has an oxymoronic flavor to it, worthy of a comment from William Osler's alter ego, Egerton Yorrick Davis (2). The danger here, of course, is the bringing of any aspect of religion into the "marketplace." Because of this danger, we must be ever-diligent to prevent a misguided religiosity in the clinic or hospital. I have seen religious icons hanging in individual physicians' offices, perhaps in an attempt to announce to their patients that they are indeed religious people. This I believe to be inappropriate. Likewise, in an article in which (ironically) Dr. Larson is also quoted (3), the author proudly quotes a hospital physician, when talking to the mother of a sick child about her child's possible recovery, as telling her that her daughter "will tell us whether she wants to go to heaven." This statement is cited as an example of how "religious" a place that hospital happens to be. It makes little difference in an ethical sense (although perhaps a great difference in a "marketplace" sense) whether this statement was greeted with appreciation or horror by the mother. In either case it is clearly inexcusable. Let us not foist our religious beliefs on others. Unfortunately, the religious zealot now has the almighty power of the "health care market" to invoke as an excuse for such self-assertion.
John Graner, MD Mayo Clinic Rochester, MN 55906 the circumstances. If the physician says this to a patient with whom she has had no discussion about spiritual belief, then we would agree that this is inappropriate. If, on the other hand, the physician knows the family believes in heaven, then such a comment as was quoted in the article would be appropriate.
This clinical example highlights the need for courses on spirituality in medical schools. Spiritual issues are often operative in patients' lives, particularly in the context of their coping with chronic and serious illness (1) . In addition, issues of meaning and suffering in patients' lives come up in the context of the physician-patient relationship. Therefore, it is critical that physicians be better educated in addressing spiritual issues appropriately with patients and their families. The medical school courses emphasize respect for patients' belief systems when patients use them to cope with their health and illness (2) . Proselytizing or prescribing religious activities for patients is not recommended or encouraged. Physicians need to honor the trust patients give them by respecting their patients' autonomy. Caregivers should be responsive to their patients' spiritual needs but also be aware of appropriate ethical boundaries (3). Thus, the physician in the preceding example would know not to use religious concepts in a discussion with a patient unless that physician had asked about the patient's belief system and used references congruent with the patient's beliefs.
A spiritual history is an inquiry into what gives meaning to a person's life. It is one way to get to understand a patient more fully (4). It is not a substitute for chaplains. In fact, integral to the spiritual history is referral to chaplains and other spiritual care providers. The key element of the spiritual history is listening to what is important to the patient and being truly present to the patient. This is at the root of compassionate caregiving.
The Association of American Medical Colleges emphasizes the need to educate medical students to be compassionate. In their Medical School Objectives Project, they note that "Physicians must be compassionate . . . they must seek to understand the meaning of the patients' stories in the context of the patients' beliefs, and family and cultural values" (5). We would agree and thus support current courses in spirituality and health in medical schools and residencies. 
Intractable Terminal Suffering
TO THE EDITOR:
No doubt BG, the patient described in Quill and Byock's paper (1), was grateful for the assistance he received at the end of his life, and his palliative care attendants would say he died peacefully. But no amount of sophistry can hide the fact that he did not get the treatment he wanted: His statement "I just want to go to sleep and not wake up" reveals his true wishes, which are not always explicitly expressed by dying patients. This requires exploration of such gambits, but many in palliative care do not want to open these doors. Instead, the patient had to endure 9 days of dehydration (hardly a choice; it seems to have been his only option), an immense emotional effort, which would be described as medical neglect except that it was "voluntary." On the 10th day, he was granted some palliation by sedation. Do the authors seriously suggest that this is a credible alternative to medically assisted suicide?
I have, under duress, used terminal sedation and withdrawal of foods and fluids for the hastening of death to relieve terminal suffering when these were the only available options. I have also assisted suicide by lethal oral barbiturates and can categorically say that there is no comparison in the quality and dignity of the death as far as the patient and her family are concerned. The former methods may preserve the "moral" and legal integrity of the physician, but they do not serve the best interests of the patient and her family.
Quill and Byock state that, with regard to terminal sedation, hydration and mechanical ventilation are not instituted or are usually withdrawn "because they could prolong the dying process without contributing to the quality of the patient's remaining life." Since a deliberately anesthetized patient has no quality of life, the sedatives of terminal sedation equally prolong the dying process, without contributing to the quality of the patient's life, in comparison to a lethal dose of barbiturates, which achieves the same end with dignity but without futility or hypocrisy.
Is this the same Timothy Quill who treated Diana? In 1991, he said that "Suffering can be lessened to some extent, but in no way eliminated or made benign, by the careful intervention of a competent caring physician, given current legal constraints" (2) . This is still true today, except in Oregon.
Government and Medical Education
TO THE EDITOR: Dr. Kefalides did a nice job summarizing some of the issues surrounding the role of government in medical education (1).
However, I was dismayed to read a section quoting Wanda Wallis from the Medical Board of California. She states that she was unable to document the compliance of Loyola Stritch School of Medicine with the family medicine clerkship requirement. I am happy to report that our family medicine clerkship, required at the school, has been the highest-rated clerkship since 1995. Family medicine is the second most frequently chosen specialty of our graduates (internal medicine is first), and many of our graduates have gone to California for their residency training. Our students rotate through a variety of sites, including community hospitals such as West Suburban Hospital in Oak Park, Illinois. Family medicine is a large part of the curriculum at Loyola Stritch, and the article leads one to think otherwise. Specifically, I am concerned that anyone reading the article would conclude that the school does not have a required family medicine clerkship. This could not be further from the truth. Some residents commit to a subspecialty training program, then fail to follow through, leaving the program high and dry for a fellow. This occurs only too often when a resident is in an exchange visa program, which stipulates that after fellowship the physician must leave the United States for at least 2 years. However, if a graduate of a residency program practices in a medically underserved area in the United States after residency, he or she may obtain a waiver for this waiting period.
Sadly, I have seen residents look me straight in the eye and assure me that they are committed to doing a fellowship. Then, after contracting for a position, the resident will clandestinely seek a practice in an underserved area. If such a position is obtained, the resident will withdraw from the specialty program. When the resident is confronted, I have received such replies as "I was advised not to tell you the truth, because that might prevent me from staying in this country." It is a clear "end justifies the means" message that is repeatedly offered.
The preceding may be just one narrow example of an "ethical lapse." We are still proud of the broad cultural diversity of our program's residents and faculty. If we ever hope to improve our residents' behavior, we need first to look at ourselves. Will physicians order unnecessary tests to enhance their income? Do physicians fabricate patient information to justify insurance reimbursement for a patient's needed care? It seems we need better ways to guide our residents through postresidency placement and better ethical measures for our collective behavior. 
Successful Treatment of Hepatitis C in Sickle-Cell Disease
TO THE EDITOR:
Patients with sickle-cell disease are at high risk for hepatitis C virus (HCV) infection; HCV seropositivity rates in this group are as high as 30% (1). In the U.S. population, 1.8% of patients with this disease are infected with HCV (2) . Cirrhosis caused by HCV may supervene as an important cause of death as patients with sickle-cell disease live longer. Indeed, liver transplantation for HCV-related cirrhosis has been performed in patients with sickle-cell disease (3). Although patients with sickle-cell disease commonly survive to their sixth decade (4, 5) , treatment of HCV infection in these patients has not been reported.
We evaluated a 35-year-old woman with HCV acquired from blood transfusions that had been done for hemoglobin SS sickle-cell disease. In July 1998, the patient had an HCV RNA level of 101 053 copies/mL, with mildly elevated aminotransferase levels. The albumin level was 606 mol/L, the leukocyte count was 12.9 ϫ 10 9 cells/L, the hemoglobin level was 98 g/L, the hematocrit was 0.28, the platelet count was 361 ϫ 10 9 /L, and the ferritin level was 1382 g/L. Liver biopsy disclosed portal lymphocyte infiltration and notable portal fibrosis consistent with active HCV infection. Hemosiderosis was also noted.
We instituted therapy with hydroxyurea, 500 mg orally twice daily, resulting in a fetal hemoglobin level of 0.198. We then began therapy with interferon-␣2b, 3 million U subcutaneously three times weekly, and ribavirin, 1 g orally per day. Except for mild constitutional symptoms, the patient's interferon-ribavirin treatment was notable for stable hematocrit and complete absence of painful episodes. After 20 days of treatment, liver enzyme levels were normal and HCV RNA was undetectable. On day 127 of treatment, HCV RNA remained undetectable. The patient completed 26 weeks of treatment without complication.
We subsequently treated HCV infection in a second patient with sickle-cell disease. This 61-year-old woman had an initial HCV RNA level of 292 000 copies/mL. After 3 months of interferon-ribavirin treatment, HCV RNA became undetectable. In the absence of painful episodes or worsened anemia, she is continuing therapy. Our experience suggests that antiviral HCV treatment has a broader role in the care of patients with sickle-cell disease than was previously supposed. (Figure) .
The patient had initiated troglitazone therapy 1 year before presentation. At baseline and periodic checks, liver enzyme levels were within normal limits. Other medications included ramipril, diltiazem, furosemide, insulin, and glyburide. Alcohol intake was insignificant. On evaluation at our center, total bilirubin level was 444 mol/L (26.0 mg/dL), alkaline phosphatase level was 7.36 kat/L, ALT level was 10 583 nkat/L, and AST level was 5.26 kat/L. Prothrombin time was normal. Laboratory investigation included negative results on viral serologic testing, normal immunoglobulin levels, and mild positivity for antinuclear and anti-smoothmuscle antibodies (both at a titer of 1:80). Ultrasonography and computed tomography were unremarkable. Liver biopsy showed submassive necrosis. The overall presentation was considered consistent with troglitazone-induced hepatotoxicity.
The patient was prescribed prednisone, 20 mg twice daily. Two weeks after initiation of steroid therapy, total bilirubin, AST, and ALT levels decreased to 128 mol/L (7.5 mg/dL), 1.62 kat/L, and 3450 nkat/L, respectively. At 5-month follow-up, the patient was no longer receiving steroids and had normal liver enzyme levels.
Steroids may be appropriate treatment of troglitazone-associated hepatotoxicity. Because many of these patients have progressive liver dysfunction that may lead to transplantation and death (1) (2) (3) (4) (5) , the discovery of an easily administered medical therapy would have a substantial effect on patients with this disorder. 
Isolated Elevation of Alkaline Phosphatase Level Associated with Rosiglitazone
TO THE EDITOR: A 47-year-old woman with a history of type 2 diabetes mellitus, hypertension, herpes zoster, depression, and diabetic gastroparesis presented for follow-up and routine laboratory evaluation. Her physical examination was benign, and her hepatic function panel was normal except for a serum alkaline phosphatase level elevated five times the upper limit of normal (10.93 kat/L). She had no history of liver disease, but approximately 1 year before presentation she had slightly elevated aminotransferase levels (alanine aminotransferase, 1283 nkat/L; aspartate aminotransferase, 0.73 kat/L).
Her medication regimen included metformin, 850 mg three times daily; sertraline, 50 mg/d; losartan, 50 mg twice daily; estropipate, 1.25 mg/d; and rosiglitazone, 4 mg/d. Results of liver function tests 4 months earlier were all normal (alkaline phosphatase level, 1.13 kat/L) when rosiglitazone was added to her regimen. During the intervening period, the patient was asymptomatic and no other medications were added to or removed from her regimen. Because rosiglitazone was the only change in her medications, it was suspected to be the offending agent. Rosiglitazone therapy was discontinued, and 2 weeks later her alkaline phosphate levels returned to normal (1.03 kat/L). Rechallenge was not done.
Rosiglitazone is structurally similar to the other thiazolidinediones, pioglitazone and troglitazone. Troglitazone, which has been associated with fatal hepatotoxicity, has been removed from the market. According to premarketing data, rosiglitazone was not associated with hepatotoxicity (1). Subsequently, case reports (2, 3) of two patients, each with risk factors for liver disease, have indicated that elevated liver enzyme levels were associated with rosiglitazone.
Our report of an elevated alkaline phosphatase level supports the evidence of a possible class association of liver toxicity among the thiazolidinediones. This class of medications should be used cautiously, if at all, in patients with any history of hepatic disease. Patients should be frequently monitored to ensure that hepatic damage is not occurring.
Anion Gap Acidosis Associated with Acetaminophen
TO THE EDITOR: Pyroglutamic aciduria (5-oxoprolinuria) is caused by a deficiency of gluthathione synthetase of 5-oxoprolinase. This disorder has been reported after the ingestion of therapeutic doses of acetaminophen and has been fatal (1). We report pyroglutamic aciduria developing after acetaminophen-oxycodone treatment.
A previously healthy 44-year-old woman presented with a 1-month history of back pain treated with acetaminophen-oxycodone, one to two tablets every 6 hours. Evaluation revealed a muscle strain and a fruity smell on her breath. Notable laboratory values were a CO 2 level of 15 mEq/L, anion gap of 25 mEq/L, ␤-hydroxybutyrate level of 5.3 mEq/L, lactate level of 0.9 mEq/L, acetaminophen level of 15 g/mL, and negative salicylate and alcohol levels. Acetaminophen-oxycodone therapy was discontinued. The patient could not provide an initial urine sample. Two days later, a urine sample obtained for measurement of organic acid by gas chromatography-mass spectrometry showed a pyroglutamic acid level of 554 mmol/mol creatine and 3-hydroxybutyric and acetoacetic acid. Clinical and biochemical recovery were complete.
The ␥-glutamyl cycle is important in the synthesis and metabolism of glutathione, the transport of glutathione out of the cell, and uptake of amino acids into the cell (Figure on page 752 ). Glutathione is formed from ␥-glutamylcystine and glycine in the presence of glutathione synthetase. Normally, glutathione controls its own rate of synthetase through feedback inhibition. Gluathionine deficiency leads to the overproduction of ␥-glutamylcysteine, which is subsequently converted to 5-oxoproline and cystine. 5-Oxoproline accumulates because its production exceeds the metabolic capacity of 5-oxoprolinase enzyme. The heterozygote state is characterized by a moderate reduction (50%) in the activity of glutathione synthetase, normal basal glutathione levels, and no clinical abnormalities (2) . The heterozygote state has been estimated to occur in 1/10 000 persons (3). Exposure to drugs, such as acetaminophen, that are known to deplete glutathione stores in a susceptible individual could lead to this condition (2, 3) .
We believe our patient was a heterozygote for glutathione synthetase deficiency. She lacked the clinical features of congenital glutathione deficiency, such as chronic metabolic acidosis. Unlike patients described previously, our patient had no other comorbid conditions and was not severely ill (1, 4) . One report of acute 5-oxoprolinuria after paracetamol ingestion noted normal glutathione and 5-oxoprolinase activities (5) . This suggests that other factors, including glutathione content and duration of exposure to acetaminophen, are important in determining susceptibility to this condition (2) . Acetaminophen should be withdrawn and 5-oxoproline in the urine should be measured in all patients with unexplained high serum anion gap acidosis.
Treatment of Myelodysplasia in a Patient with Active Rheumatoid Arthritis
TO THE EDITOR:
We describe a patient with the myelodysplastic syndrome in whom anemia resolved and bone marrow structure returned to normal after etanercept treatment.
The patient is a 54-year-old woman with an 11-year history of rheumatoid arthritis. Previous treatment with prednisone (Յ7.5 mg/d) and hydroxychloroquine controlled her arthritis. Her baseline complete blood count had shown mild anemia of chronic disease, with a hemoglobin level of 100 to 110 g/L.
In August 1998, the patient reported shortness of breath, and her hemoglobin level was 61 g/L. Leukocyte and platelet counts were normal. Two independent bone marrow samples revealed myelodysplasia and minimal fibrosis, and myelodysplasia was diagnosed. Findings on cytogenetic studies were normal, and no splenomegaly was noted.
In November 1998, the patient's arthritis worsened. High-dose steroid (60 mg/d) and methotrexate produced only transient joint improvement. Anemia was treated with high-dose erythropoietin, fluoxymesterone, and several blood transfusions per month. Tumor necrosis factor (TNF) appears to play a significant role in hematopoiesis. Numerous studies (1, 2) have demonstrated a suppressive effect of TNF on in vitro and in vivo hematopoiesis. Recent reports (3, 4) have demonstrated a clinical role for TNF in the pathogenesis of myelodysplasia. Our patient achieved remission status, with normalization of hematologic status and bone marrow structure, after receiving an antibody that prevents the attachment of TNF to cellular receptors. No specific therapy yet exists for the treatment of myelodysplastic syndromes (5) . We suggest further investigations into the role of TNF antagonists as potential biologic therapies for this fatal disease.
